Durable responses to Erlotinib despite KRAS mutations in two patients with metastatic lung adenocarcinoma
Author:
Funder
Oscar Lambret Cancer Center
Publisher
Elsevier BV
Subject
Oncology,Hematology
Link
http://academic.oup.com/annonc/article-pdf/21/6/1385/13783606/mdq153.pdf
Reference22 articles.
1. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib;Pao;PLoS Med,2005
2. High expression of ErbB family members and their ligands in lung adenocarcinomas that are sensitive to inhibition of epidermal growth factor receptor;Fujimoto;Cancer Res,2005
3. The impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese patients with non-small-cell lung cancer;Ichihara;Int J Cancer,2007
4. Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation;Han;Clin Cancer Res,2006
5. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer;Massarelli;Clin Cancer Res,2007
Cited by 10 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. A tyrosine kinase protein interaction map reveals targetable EGFR network oncogenesis in lung cancer;2020-07-03
2. Durable complete remission of poor performance status metastatic lung adenocarcinoma patient treated with second-line erlotinib: a case report;OncoTargets and Therapy;2017-09
3. The role of epithelial to mesenchymal transition in resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer;Translational Lung Cancer Research;2016-04
4. KRAS mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapy;Oncotarget;2015-09-15
5. Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy;Oncotarget;2015-09-03
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3